ReviewCancer discovery2014
Universes collide: combining immunotherapy with targeted therapy for cancer.
Review in Cancer discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.Journal for immunotherapy of cancer · 2021Pooled it
- Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Real-world outcomes of advanced melanoma patients not represented in phase III trials.International journal of cancer · 2020Trial
- Discovery of Cyclic Peptides Targeting the BRAF Dimer Interface as Dual Inhibitors.ACS pharmacology & translational science · 2026Article
- Detection and surgical intervention in anorectal malignant melanoma: a case report.Journal of medical case reports · 2026Article
- Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Targeting Innate Immunity in Glioma Therapy.International journal of molecular sciences · 2024Review
- Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.Current cancer drug targets · 2023Review
- Combined targeted therapy and immunotherapy for cancer treatment.World journal of clinical cases · 2021Review
- Immune System in Action.Advances in experimental medicine and biology · 2021Article
- Targeting innate sensing in the tumor microenvironment to improve immunotherapy.Cellular & molecular immunology · 2020Review
- The density and spatial tissue distribution of CD8Journal for immunotherapy of cancer · 2019Article
- Article
- Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.Journal of medicinal chemistry · 2019Article
- Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.Scientific reports · 2019Article
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.Frontiers in immunology · 2019Review
- Hexosamine Biosynthetic Pathway and Glycosylation Regulate Cell Migration in Melanoma Cells.Frontiers in oncology · 2019Article
- [Immunological foundations of modern (tumor) immunotherapy].Der Pathologe · 2018Review
- Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Journal of clinical pharmacology · 2018Review
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.OncoTargets and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThere have been significant advances in the past several years with regard to targeted therapy and immunotherapy for cancer. This is highlighted in melanoma, where treatment with targeted therapy (against the BRAF oncoprotein) results in responses in the majority of patients, although the duration of response is limited. In contrast, treatment with immunotherapy results in a lower response rate, but one that tends to be more durable. Insights about mechanisms of response and potential synergy between these treatment strategies for melanoma are a focus of this review, with opportunities to extend these insights to the treatment of other cancers. SIGNIFICANCE: Two major advances in melanoma have occurred concurrently and involve treatment with targeted therapy and immune checkpoint blockade. However, each of these approaches has limitations with regard to overall response rates or duration of response. To address this, investigators have proposed combining these strategies, and this concept is being tested empirically in clinical trials. There is a scientific rationale supporting the combination of targeted therapy and immunotherapy, and these concepts are discussed herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.